After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.